Beijing Tide Pharmaceutical, a subsidiary of Sino Biopharmaceutical (SBHMY), has initiated Phase II clinical trials for TRD205, a first-in-class AT2R antagonist targeting chronic post-surgical neuropathic pain (CPSP). The drug represents a breakthrough in non-opioid pain management, addressing a condition affecting 10% of surgical patients globally (30 million cases annually). TRD205 works by selectively blocking AT2R activation, which triggers pain sensitization, offering a safer alternative to opioids that show efficacy in only 25% of patients. The Phase II trial will evaluate 184 CPSP patients over six weeks. The drug has received approvals from both FDA and NMPA, with Phase I trials showing positive safety profiles. TRD205 targets a potential $10 billion market, with expansion possibilities into diabetic neuropathy and postherpetic neuralgia.
Loading...
Loading translation...
Positive
First-in-class AT2R antagonist entering Phase II trials with potential to be first approved in class
Addresses large market opportunity of 30 million CPSP cases annually
Novel non-opioid mechanism avoiding addiction and respiratory depression risks
Dual FDA and NMPA approvals secured for clinical trials
Favorable safety and pharmacokinetic profiles demonstrated in Phase I
Targeting $10 billion market with potential expansion into additional indications
Negative
Early-stage drug development with no guarantee of clinical success
Competition emerging from other companies like Lilly-partnered CFTX-1554
Extended timeline required for Phase II completion and potential approval
News Market Reaction – SBHMY
+46.84%
+46.84%Session move
In the trading session that priced this news, SBHMY gained 46.84%, reflecting a significant positive market reaction.
BEIJING, May 5, 2025 /PRNewswire/ -- Beijing Tide Pharmaceutical Co., Ltd., a subsidiary of Sino Biopharmaceutical Limited (1177.HK), has achieved a milestone in developing its first-in-class analgesic drug (research code: TRD205), a highly selective angiotensin II type 2 receptor (AT2R) antagonist, with the first patient successfully dosed. As the first globally innovative drug targeting chronic post-surgical neuropathic pain (CPSP) to enter Phase II clinical development, TRD205 is positioned to overcome the limitations of existing opioid therapies and provide a safer, more effective solution for hundreds of millions of patients worldwide.
Mechanistic Breakthrough: Pioneering Non-Opioid Analgesic Pathways via AT2R Targeting
CPSP affects approximately 10% of surgical patients globally, translating to over 30 million cases annually. Current treatments face significant constraints: opioids demonstrate efficacy in only 25% of patients while carrying risks of addiction and depression, whereas NSAIDs and antidepressants show limited efficacy against neuropathic pain. TRD205's core innovation lies in its precise inhibition of AT2R, a receptor whose abnormal activation post-peripheral nerve injury triggers macrophages to release reactive oxygen/nitrogen species. This process exacerbates calcium influx in dorsal root ganglion (DRG) sensory neurons, amplifying pain sensitization. By selectively blocking this pathway, TRD205 suppresses pain signaling at its source without engaging the central nervous system, thereby avoiding opioid-related risks such as addiction and respiratory depression. The drug has secured clinical trial approvals from both the U.S. FDA and China's NMPA, with Phase I trials in healthy Chinese volunteers confirming favorable safety and pharmacokinetic profiles.
Addressing the Urgent Unmet Need in CPSP: A Public Health Priority
CPSP defined as pain persisting for over three months following surgery, impacts approximately 10% of the 320 million annual surgical patients globally. It is particularly prevalent after procedures such as limb amputation (50%-85%), thoracotomy (30%-50%), breast surgery (25%-50%), and hernia repair (5%-35%), etc. Beyond physical suffering, CPSP is closely linked to anxiety, depression, and other symptoms. Existing therapies address less than 30% of clinical demand, highlighting the critical need for novel mechanisms like TRD205's opioid-free approach. The Phase II study plans to enroll 184 patients with CPSP to evaluate pain score (NRS) improvements across dose groups over a six-week period.
Market Potential and Strategic Positioning in a $10 Billion Landscape
Global AT2R-targeted drug development remains nascent, with only a few competitors like Lilly-partnered CFTX-1554 (Phase I). TRD205's approval would make it the first AT2R therapy for CPSP, with expansion potential into indications such as diabetic neuropathy and postherpetic neuralgia—a combined market exceeding $10 billion.
TRD205's Phase II trial initiation marks a pivotal transition from opioid-dependent analgesia to precision targeting. Successful clinical validation would deliver a novel therapeutic paradigm for over hundreds of millions of patients globally.
FAQ
What is TRD205 and how does it work for chronic pain?
TRD205 is a first-in-class AT2R antagonist that selectively blocks AT2R activation, which triggers pain sensitization. Unlike opioids, it suppresses pain signaling without engaging the central nervous system, avoiding addiction risks.
What are the market opportunities for SBHMY's TRD205?
TRD205 targets a $10 billion market opportunity, addressing 30 million annual CPSP cases globally, with potential expansion into diabetic neuropathy and postherpetic neuralgia.
How does TRD205's efficacy compare to existing pain treatments?
While current opioids show efficacy in only 25% of patients and carry addiction risks, TRD205 offers a novel non-opioid approach with potentially better safety profile, demonstrated in Phase I trials.
What is the current development stage of SBHMY's TRD205?
TRD205 has entered Phase II clinical trials with 184 CPSP patients, following successful Phase I completion and approvals from both U.S. FDA and China's NMPA.
Who are the competitors for SBHMY's TRD205 in AT2R pain treatment?
The AT2R drug development space is nascent, with only a few competitors, including Lilly-partnered CFTX-1554 in Phase I trials.
